A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

NCT04094610 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

75

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced Solid Tumors
Metastatic Solid Tumors
Lymphoma
Primary CNS Tumors

Interventions

DRUG: Oral repotrectinib (TPX-0005)

Sponsor

Turning Point Therapeutics, Inc.